Poseida Therapeutics - PSTX Stock Forecast, Price & News

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics Trading Up 6.3 %

Shares of Poseida Therapeutics stock traded up $0.26 during trading hours on Friday, reaching $4.37. 13,530 shares of the company's stock were exchanged, compared to its average volume of 3,732,693. Poseida Therapeutics has a 52-week low of $1.82 and a 52-week high of $11.10. The firm has a market capitalization of $361.53 million, a price-to-earnings ratio of -1.76 and a beta of 0.52. The company has a fifty day moving average of $2.69 and a 200-day moving average of $3.28. The company has a current ratio of 4.34, a quick ratio of 4.34 and a debt-to-equity ratio of 0.56.

Poseida Therapeutics (NASDAQ:PSTX - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.35). The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.50 million. Sell-side analysts forecast that Poseida Therapeutics will post -3.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on PSTX. Piper Sandler upped their target price on Poseida Therapeutics from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Tuesday. Cantor Fitzgerald began coverage on Poseida Therapeutics in a research note on Friday, May 13th. They issued a "buy" rating and a $24.00 target price on the stock. Finally, BTIG Research reduced their target price on Poseida Therapeutics from $40.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 13th.

Insider Buying and Selling

In other news, Chairman Eric Ostertag bought 142,857 shares of the business's stock in a transaction that occurred on Monday, August 8th. The shares were acquired at an average cost of $3.50 per share, with a total value of $499,999.50. Following the transaction, the chairman now owns 838,824 shares of the company's stock, valued at approximately $2,935,884. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Life Sciences Holdings L. Malin purchased 2,150,000 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $7,525,000.00. Following the acquisition, the insider now owns 11,835,673 shares in the company, valued at $41,424,855.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Eric Ostertag purchased 142,857 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was bought at an average price of $3.50 per share, with a total value of $499,999.50. Following the completion of the acquisition, the chairman now owns 838,824 shares in the company, valued at approximately $2,935,884. The disclosure for this purchase can be found here. Corporate insiders own 29.20% of the company's stock.